BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 27865680)

  • 1. Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction.
    González-Cambeiro MC; López-López A; Abu-Assi E; Raposeiras-Roubín S; Peña-Gil C; García-Acuña J; González-Juanatey R
    Rev Port Cardiol; 2016 Dec; 35(12):645-653. PubMed ID: 27865680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention.
    Byun JK; Choi BG; Rha SW; Choi SY; Jeong MH;
    Atherosclerosis; 2018 Oct; 277():130-135. PubMed ID: 30212681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction.
    Raposeiras-Roubín S; Abu-Assi E; Cespón-Fernández M; Ibáñez B; García-Ruiz JM; D'Ascenzo F; Simao Henriques JP; Saucedo J; Caneiro-Queija B; Cobas-Paz R; Muñoz-Pousa I; Wilton SB; González Juanatey JR; Kikkert WJ; Núñez-Gil I; Ariza-Solé A; Song X; Alexopoulos D; Liebetrau C; Kawaji T; Gaita F; Huczek Z; Nie SP; Yan Y; Fujii T; Correia L; Kawashiri MA; Kedev S; Southern D; Alfonso E; Terol B; Garay A; Zhang D; Chen Y; Xanthopoulou I; Osman N; Möllmann H; Shiomi H; Giordana F; Kowara M; Filipiak K; Wang X; Fan JY; Ikari Y; Nakahayshi T; Sakata K; Yamagishi M; Kalpak O; Íñiguez-Romo A
    Rev Esp Cardiol (Engl Ed); 2020 Feb; 73(2):114-122. PubMed ID: 31105064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) Registry.
    Song PS; Seol SH; Seo GW; Kim DK; Kim KH; Yang JH; Hahn JY; Gwon HC; Ahn Y; Jeong MH; Song YB; Kim DI;
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):439-49. PubMed ID: 26153396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin Receptor Blockers as an Alternative to Angiotensin-Converting Enzyme Inhibitors in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
    Lim S; Choo EH; Choi IJ; Ihm SH; Kim HY; Ahn Y; Chang K; Jeong MH; Seung KB
    J Korean Med Sci; 2019 Nov; 34(45):e289. PubMed ID: 31760711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Kim S; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Angiology; 2020 Feb; 71(2):139-149. PubMed ID: 31694385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of renin angiotensin system inhibitor on 3-year clinical outcomes in acute myocardial infarction patients with preserved left ventricular systolic function: a prospective cohort study from Korea Acute Myocardial Infarction Registry (KAMIR).
    Kim KH; Choi BG; Rha SW; Choi CU; Jeong MH;
    BMC Cardiovasc Disord; 2021 May; 21(1):251. PubMed ID: 34020593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison Between Beta-Blockers with Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers with Angiotensin II Type I Receptor Blockers in ST-Segment Elevation Myocardial Infarction After Successful Percutaneous Coronary Intervention with Drug-Eluting Stents.
    Kim YH; Her AY; Jeong MH; Kim BK; Lee SY; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Cardiovasc Drugs Ther; 2019 Feb; 33(1):55-67. PubMed ID: 30632033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers in acute ST-segment elevation myocardial infarction patients with diabetes mellitus undergoing percutaneous coronary intervention.
    Choi SY; Choi BG; Rha SW; Byun JK; Shim MS; Li H; Mashaly A; Choi CU; Park CG; Seo HS; Oh DJ; Jeong MH;
    Int J Cardiol; 2017 Dec; 249():48-54. PubMed ID: 28867244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary prevention of myocardial infarction with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients with rheumatoid arthritis-A nationwide cohort study.
    Lin TT; Wu CK; Liao MT; Yang YH; Chen PC; Yeih DF; Lin LY
    PLoS One; 2017; 12(12):e0188720. PubMed ID: 29216228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
    Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
    Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcomes at 2 Years Between Beta-Blockade with ACE Inhibitors or ARBs in Patients with AMI Who Underwent Successful PCI with DES: A Retrospective Analysis of 23,978 Patients in the Korea AMI Registry.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Am J Cardiovasc Drugs; 2019 Aug; 19(4):403-414. PubMed ID: 30788675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of renin-angiotensin system antagonists on long-term mortality post-percutaneous coronary intervention in reduced and preserved ejection fraction.
    Prosser HC; Peck KY; Dinh D; Roberts L; Chandrasekhar J; Brennan A; Duffy SJ; Clark D; Ajani AE; Oqueli E; Sebastian M; Reid CM; Freeman M; Sajeev JK; Teh AW
    Clin Res Cardiol; 2022 Jul; 111(7):776-786. PubMed ID: 35050405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
    Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
    Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
    Lee J; Lee S
    Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
    Shih CJ; Chu H; Ou SM; Chen YT
    Int J Cardiol; 2015 Nov; 199():283-9. PubMed ID: 26218587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct survival benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers in revascularized coronary artery disease patients according to history of myocardial infarction.
    Nishino T; Furukawa Y; Kaji S; Ehara N; Shiomi H; Kim K; Kitai T; Kinoshita M; Morimoto T; Sakata R; Kimura T;
    Circ J; 2013; 77(5):1242-52. PubMed ID: 23291989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.
    Hoang V; Alam M; Addison D; Macedo F; Virani S; Birnbaum Y
    Cardiovasc Drugs Ther; 2016 Apr; 30(2):189-98. PubMed ID: 26861251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
    Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
    JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with Optimal Dose Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Has a Positive Effect on Long-Term Survival in Older Individuals (Aged >70 Years) and Octogenarians with Systolic Heart Failure.
    Sargento L; Simões AV; Longo S; Lousada N; Dos Reis RP
    Drugs Aging; 2016 Sep; 33(9):675-83. PubMed ID: 27568454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.